| Completed | Effectiveness of Ammonium Chloride in Reducing Viral Load NCT07254052 | National and Kapodistrian University of Athens | — |
| Unknown | Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict S NCT05394623 | The First Affiliated Hospital with Nanjing Medical University | — |
| Completed | Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Sa NCT05284097 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine i NCT05422326 | Seqirus | Phase 2 |
| Completed | Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe NCT05307991 | University of North Carolina, Chapel Hill | — |
| Completed | EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19 NCT04822818 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men NCT04772469 | University of California, San Francisco | N/A |
| Terminated | Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19) NCT04664075 | Imperial College London | — |
| Completed | A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety NCT04644484 | Synermore Biologics (Suzhou) Co., Ltd. | Phase 3 |
| Completed | Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 NCT04476979 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Unknown | Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration NCT04627623 | Medical University of Silesia | — |
| Completed | COVID-19 and SARS-CoV-2 Detection in Saliva NCT04517682 | Ambry Genetics | — |
| Unknown | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 NCT04365101 | Celularity Incorporated | Phase 1 / Phase 2 |
| Completed | ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Ca NCT04367740 | University of North Carolina, Chapel Hill | — |
| Completed | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocom NCT04380701 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | Convalescent Plasma Collection and Treatment in Pediatrics and Adults NCT04376034 | West Virginia University | Phase 3 |
| Unknown | Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination NCT03776760 | Kirby Institute | — |
| Completed | Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly NCT03739112 | Medicago | Phase 3 |
| Unknown | Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine NCT03776994 | SRI International | Phase 1 |
| Completed | Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2 NCT03392207 | Butantan Institute | — |
| Completed | Centralized Reminder Recall - Flu RCT2 NCT03294473 | University of California, Los Angeles | N/A |
| Completed | Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adult NCT03321968 | Medicago | Phase 3 |
| Completed | Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vac NCT03301051 | Medicago | Phase 3 |
| Completed | VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents NCT03110770 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | DNA and RNA Viruses of the Blood Virome of Allogeneic Hematopoietic Stem Cell Transplant Recipients NCT03642977 | University Hospital, Geneva | — |
| Completed | Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adul NCT02831751 | Medicago | Phase 2 |
| Completed | Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults NCT02768805 | Medicago | Phase 2 |
| Terminated | Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixe NCT02613403 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza NCT02233816 | Medicago | Phase 2 |
| Completed | Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the NCT02236052 | Medicago | Phase 2 |
| Terminated | Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic H NCT02120274 | Federal University of São Paulo | Phase 4 |
| Completed | Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adul NCT02022163 | Medicago | Phase 1 |
| Completed | Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults NCT01991587 | Medicago | Phase 1 / Phase 2 |
| Completed | Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine. NCT01991561 | Medicago | Phase 2 |
| Completed | DNA-based Influenza Vaccine in the Elderly NCT01587131 | University of Manitoba | Phase 1 |
| Completed | Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, NCT02630082 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine NCT01244867 | Medicago | Phase 2 |
| Completed | Clinic-based ART Diagnostic Evaluation NCT01791556 | Walter Reed Army Institute of Research (WRAIR) | N/A |
| Completed | Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults NCT00984945 | Medicago | Phase 1 |
| Completed | Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis NCT05065905 | SPP Pharmaclon Ltd. | Phase 1 / Phase 2 |